Amivantamab in Adenoid Cystic Carcinoma

Sponsor

Trisha Wise-Draper (Other)

Overall Status

Recruiting

CT.gov ID

NCT05074940

Collaborator

(none)

Enrollment

Location

Arm

Anticipated Duration (Months)

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.

Condition or Disease	Intervention/Treatment	Phase
Salivary Gland Cancer	Drug: Amivantamab	Phase 2

Detailed Description

ACC is a rare cancer of salivary glands and other glandular tissue. It is slow growing and is usually treated with surgery and radiation. However, this type of cancer tends to have a high rate of recurrence and metastatic spread, which develops over several years. We hypothesize that amivantamab, a bispecific EGFR and MET inhibitor will be efficacious in ACC. Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

Study Design

Study Type:

Interventional

Anticipated Enrollment :

18 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

Open-label phase II single arm trialOpen-label phase II single arm trial

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase II Study to Evaluate Amivantamab in Recurrent and Metastatic Adenoid Cystic Carcinoma

Actual Study Start Date :

Aug 5, 2022

Anticipated Primary Completion Date :

Aug 5, 2023

Anticipated Study Completion Date :

Aug 5, 2028

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Amivantamab Amivantamab weekly for the first cycle and biweekly thereafter.	Drug: Amivantamab Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

Arm

Intervention/Treatment

Experimental: Amivantamab

Amivantamab weekly for the first cycle and biweekly thereafter.

Drug: Amivantamab

Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

Outcome Measures

Primary Outcome Measures

Overall response rate measured by RECIST criteria [2 years]
To determine the overall response rate in patients with recurrent and metastatic adenoid cystic carcinoma treated with amivantamab.

Secondary Outcome Measures

Progression free survival -measured as time of treatment allocation to confirmed progressive disease or death. [5 years]
To determine the progression free survival and overall survival in patients with recurrent and metastatic adenoid cystic carcinoma treated with amivantamab.
Safety- measured by CTCAE v5 criteria and toxicity evaluation [5 years]
To determine safety of amivantamab in patients with recurrent and metastatic adenoid cystic carcinoma.

Other Outcome Measures

Molecular signatures of response and resistance- measured by comprehensive analysis of Transcriptome Sequencing [2 years]
To determine the molecular signatures of response and resistance to amivantamab
Percent immune cell infiltration in responders versus non-responders, determined by IHC and/or IF [2 years]
To determine immune cell infiltration in biopsy samples and correlation with response.
Quality of life - measured via FACT-HN [2 years]
To evaluate the effect of amivantamab on patient quality of life using standardized patient reported outcome surveys.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Pathologically or cytologically confirmed adenoid cystic carcinoma. Non-salivary gland primary sites are allowed.
Recurrent and/or metastatic disease not amenable to other curative intent therapy.
Presence of measurable disease as defined by RECIST v1.1
Age ≥18 years.
ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).
Patients must have adequate organ and marrow function
Known human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression in the last 4 weeks.
Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

Exclusion Criteria

History of allergy or intolerance to study drug components.
Prior use of amivantamab
Patients who have had chemotherapy or immunotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Palliative radiotherapy is allowed and does not require washout as long as it does not include a target lesion.
Positive hepatitis B (hepatitis B virus [HBV]) surface antigen (HBsAg) Note: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing.
Positive hepatitis C antibody (anti-HCV). Note: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible.
Other clinically active or chronic liver disease.
Participant has active cardiovascular disease including, but not limited to:

A medical history of deep vein thrombosis or pulmonary embolism within 1 month prior to first dose of study drug or any of the following within 6 months prior to the first dose of study drug: myocardial infarction, unstable angina, stroke, transient ischemic attack, uncontrolled hypertension, or clinically significant cardiac arrythmia. Clinically non-significant thrombosis, such as non-obstructive catheter-associated clots, are not exclusionary.
Prolonged corrected QTcF >470 msec),
Congestive heart failure (CHF), defined as New York Heart Association (NYHA) class III-IV or hospitalization for CHF (any NYHA class; refer to Appendix: New York Heart Association Criteria) within 6 months of randomization.

Subject has uncontrolled inter-current illness, including but not limited to poorly controlled diabetes, ongoing or active infection (i.e., has discontinued all antibiotics for at least one week prior to first dose of study drug), or psychiatric illness/social situation that would limit compliance with study requirements. Subjects with medical conditions requiring chronic continuous oxygen therapy are excluded.
Active or past medical history of Interstitial lung disease (ILD)/pneumonitis, including drug-induced ILD/pneumonitis or radiation pneumonitis requiring treatment with prolonged steroids or other immune suppressive agents that is unresolved or resolved within the last 3 months.
Immune-mediated rash from checkpoint inhibitors that has not resolved prior to enrollment.
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia or Grade 2 neuropathy.
Patients who are receiving any other investigational agents. Patients who have received other investigational agents previously who are no longer receiving these investigational agents may be eligible at the discretion of the PI. A 30 day washout from last dose of previous anticancer drug is required.